2024/10/22 更新

写真a

カルベ ケンノスケ
加留部 謙之輔
KARUBE Kennosuke
所属
大学院医学系研究科 総合医学専攻 高次医用科学 教授
大学院担当
大学院医学系研究科
学部担当
医学部 医学科
職名
教授

学位 1

  1. 医学博士 ( 2006年3月   九州大学 ) 

 

論文 31

  1. Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma.

    Takai M, Shimada K, Furukawa K, Yamaga Y, Yoshiyama S, Kagaya Y, Suzuki T, Hayashi K, Shimada S, Karube K, Kiyoi H

    Cancer science     2024年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1111/cas.16310

    PubMed

  2. Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

    Rivas-Delgado, A; López, C; Clot, G; Nadeu, F; Grau, M; Frigola, G; Bosch-Schips, J; Radke, J; Ishaque, N; Alcoceba, M; Tapia, G; Luizaga, L; Barcena, C; Kelleher, N; Villamor, N; Baumann, T; Muntañola, A; Sancho-Cia, JM; García-Sancho, AM; Gonzalez-Barca, E; Matutes, E; Brito, JA; Karube, K; Salaverria, I; Enjuanes, A; Wiemann, S; Heppner, FL; Siebert, R; Climent, F; Campo, E; Giné, E; López-Guillermo, A; Beà, S

    HEMASPHERE   8 巻 ( 10 ) 頁: e70024   2024年10月

     詳細を見る

    記述言語:英語   出版者・発行元:HemaSphere  

    Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B-cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88L265P, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.

    DOI: 10.1002/hem3.70024

    Web of Science

    Scopus

    PubMed

  3. Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms 査読有り

    Seki, M; Satou, A; Funato, R; Tamaki, T; Wada, N; Nakada, N; Matsumoto, H; Nakazato, I; Wada, E; Sakurai, K; Tsuzuki, T; Karube, K

    PATHOLOGY INTERNATIONAL   74 巻 ( 9 ) 頁: 530 - 537   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Pathology International  

    The identification of CD30 expression by immunohistochemistry is essential for the treatment of lymphomas using an antibody-drug conjugate targeting CD30. However, no standardized protocol for CD30 staining has been available. In this study, we compared three common automated immunostaining platforms {Bond III (B III), Dako Omnis (DO) and Ventana BenchMark ULTRA (VBMU)}. A primary antibody for CD30, the Ber-H2 clone, was diluted 50- to 400-fold for B III and DO, and ready-to-use antibody was used for VBMU. An enhancement step using a linker was introduced in all protocols. First, several candidate dilutions were selected for each platform by staining six cases. These candidate conditions were then confirmed with 60 cases of various types of peripheral T-cell lymphomas (PTCLs). The concordance rates of CD30 expression among platforms differed depending on cutoff values and antibody dilutions, except for anaplastic large cell lymphoma. The concordance rates among three platforms in the evaluation of “positive” or “negative” were 100% and 97% when the cutoff values were 1% and 10% respectively, if using 400-diluted antibody in B III and 100-diluted antibody in DO. This study demonstrated the feasibility of equalizing CD30 staining of PTCLs among different platforms by adjusting protocols.

    DOI: 10.1111/pin.13472

    Web of Science

    Scopus

    PubMed

  4. Small cell pattern of ALK-negative anaplastic large cell lymphoma with double-hit rearrangements of <i>DUSP22</i> and <i>TP63</i>

    Niiyama-Uchibori, Y; Mizutani, S; Tsukamoto, T; Okamoto, H; Ide, D; Onishi, A; Kato, D; Fujino, T; Shimira, Y; Miyagawa-Hayashino, A; Konishi, E; Karube, K; Nannya, Y; Kuroda, J

    EJHAEM   5 巻 ( 4 ) 頁: 798 - 801   2024年8月

     詳細を見る

    記述言語:英語  

    DOI: 10.1002/jha2.960

    Web of Science

    PubMed

  5. New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications

    Karube, K; Satou, A; Kato, S

    INTERNATIONAL JOURNAL OF HEMATOLOGY     2024年5月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Hematology  

    In 2024, the World Health Organization (WHO) launched a new classification of lymphoid neoplasms, a revision of the previously used Revised 4th Edition of their classification (WHO-4R). However, this means that two classifications are now in simultaneous use: the 5th Edition of the WHO classification (WHO-5) and the International Consensus Classification (ICC). Instead of a comprehensive review of each disease entity, as already described elsewhere, this review focuses on revisions made in both the WHO-5 and ICC from WHO-4R and discrepancies between them regarding B-cell neoplasms. Similarities include cutaneous marginal zone lymphoma, cold agglutinin disease, non-primary effusion lymphoma-type effusion-based lymphoma, and gray zone lymphoma. Differences include plasma cell neoplasms, high-grade B-cell lymphoma (double hit lymphoma), follicular lymphoma, LPD with immune deficiency and dysregulation, extranodal large B-cell lymphoma, transformations of indolent B-cell lymphomas, and diffuse large B-cell lymphoma, not otherwise specified. Understanding the similarities and differences between the two latest classifications will aid daily diagnostic practice and future research on lymphoid neoplasms.

    DOI: 10.1007/s12185-024-03781-5

    Web of Science

    Scopus

    PubMed

  6. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma

    Liu, F; Tian, SF; Liu, Q; Deng, YF; He, QY; Shi, QY; Chen, G; Xu, XL; Yuan, JY; Nakamura, S; Karube, K; Wang, Z

    CANCER MEDICINE   13 巻 ( 4 ) 頁: e6995   2024年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Medicine  

    Background: Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV-posDLBCL) is an aggressive B-cell lymphoma that often presents similar morphological and immune phenotype features to that of EBV-negative DLBCL (EBV-negDLBCL). Aims and Methods: To better understand their difference in genomic landscape, we performed whole-exome sequencing (WES) of EBV-posDLBCL and EBV-negDLBCL. Results: This analysis revealed a new mutational signature 17 (unknown) and signature 29 (smoking) in EBV-posDLBCL as well as a specific mutational signature 24 (associated with aflatoxin) in EBV-negDLBCL. Compared with EBV-negDLBCL, more somatic copy number alterations (CNAs) and deletions were detected in EBV-posDLBCL (p = 0.01). The most frequent CNAs specifically detected in EBV-posDLBCL were gains at 9p24.1 (PDL1 and JAK2), 8q22.2-q24.23 (DEPTOR and MYC), and 7q31.31-q32.2 (MET), which were validated in additional EBV-posDLBCL cases. Overall, 53.7% (22/41) and 62.9% (22/35) of the cases expressed PD-L1 and c-MET, respectively, in neoplastic cells, whereas only 15.4% (4/26) expressed c-MYC. Neoplastic c-MET expression was positively correlated with PD-L1 (p < 0.001) and MYC expression (p = 0.016). However, EBV-posDLBCL cases did not show any differences in overall survival between PD-L1-, c-MET-, or c-MYC-positive and -negative cases or between age-related groups. Analysis of the association between somatic mutation load and EBV status showed no difference in the distribution of tumor mutant burden between the two lymphomas (p = 0.41). Recurrent mutations in EBV-posDLBCL implicated several genes, including DCAF8L1, KLF2, and NOL9, while in EBV-negDLBCL, ANK2, BPTF, and CNIH3 were more frequently mutated. Additionally, PIM1 is the most altered gene in all the WES-detected cases. Conclusions: Our results confirm that genomic alteration differs significantly between EBV-posDLBCL and EBV-negDLBCL, and reveal new genetic alterations in EBV-posDLBCL. The positive correlation of c-MET and PD-L1/c-Myc expression may be involved in the pathogenesis of EBV-posDLBCL, which is should be explored prospectively in trials involving MET-directed therapies.

    DOI: 10.1002/cam4.6995

    Web of Science

    Scopus

    PubMed

  7. 症例 肝紫斑病のEOB-MRI所見:2例報告

    佐東 征記, 安座間 喜明, 木村 隆, 上里 安範, 加留部 謙之輔, 伊良波 祥子, 樋口 佳代子, 西江 昭弘

    臨床放射線   69 巻 ( 1 ) 頁: 123 - 130   2024年1月

     詳細を見る

    出版者・発行元:金原出版  

    DOI: 10.18888/rp.0000002621

    CiNii Research

  8. Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT

    Nakamura, T; Tatetsu, H; Higuchi, Y; Endo, S; Shiraishi, S; Kawanaka, K; Imakane, D; Sonoda, M; Furuta, R; Shichijo, T; Honda, Y; Karube, K; Mikami, Y; Nosaka, K; Matsuoka, M; Yasunaga, J

    Journal of Clinical and Experimental Hematopathology   64 巻 ( 1 ) 頁: 45 - 51   2024年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 リンパ網内系学会  

    Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma (NHL) with poor prog-nosis, particularly in relapsed or refractory patients. Thus, timely detection of relapse and appropriate disease management are crucial. We present two patients with ENKTL, wherein positron emission tomography-computed tomography (PET-CT) with total-body coverage after induction therapy, detected newly relapsed regions in the bone marrow of the lower leg prior to pro-gression. Case 1: A 47-year-old woman with nasal obstruction, showing 18F-fluoro-deoxyglucose (FDG) uptake in the nasal cavity (Lugano stage IE). After induction therapy (RT-2/3 DeVIC), PET-CT revealed abnormal uptake only in the right fibula. Case 2: A 68-year-old man with a skin nodule/ulcer and an enlarged right inguinal lymph node was diagnosed with advanced ENKTL. A PET-CT scan revealed abnormal uptake in the subcutaneous mass of the right medial thigh, lymph nodes, and descending colon (Lugano stage IV). After induction therapy, PET-CT revealed new abnormal uptake only in the left tibia. In both patients, CT-guided biopsy confirmed ENKTL recurrence. Moreover, PET-CT with whole-body coverage was useful for the timely assessment of relapse and detection of asymptomatic bone involvement. This approach allowed for modifications to treatment strategies in certain patients.

    DOI: 10.3960/jslrt.23046

    Web of Science

    Scopus

    PubMed

    CiNii Research

  9. Follicular lymphoma with Epstein-Barr virus-associated transformation: A case report and review of the literature

    Tsuyuki, Y; Karube, K

    Journal of Clinical and Experimental Hematopathology   64 巻 ( 2 ) 頁: 144 - 148   2024年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 リンパ網内系学会  

    Follicular lymphoma (FL) is a common type of B-cell lymphoma, accounting for about 20% of all lymphomas. Although FL is primarily characterized by an indolent clinical course, histological transformation (HT) remains one of the significant challenges in managing patients with FL. Here, we present a case of FL with partial large-cell transformation due to Epstein-Barr Virus (EBV) arising in a 50-year-old Japanese woman with no known immunodeficiency. Immunohistochemical studies revealed that medium-sized FL cells expressed CD20, CD10, BCL2, and BCL6, whereas large cells were positive for CD20, and MUM1. In situ hybridization (ISH) revealed large cells to be positive for EBV-encoded small RNA (EBER) and further immunohistochem-ical investigation demonstrated EBER+ cells to express latent membrane protein 1 (LMP1). The Ki-67 index was about 30% in FL cells, and over 70% in large cells. Fluorescence in situ hybridization for BCL2 combined with EBER-ISH identified BCL2 rearrangement in both EBV-infected large cells and EBV-uninfected FL cells, suggesting these two components were clonally related. These findings indicate that EBV contributes to the transformation of FL. As far as the authors could find, only four previous cases of FL development to EBV-positive aggressive lymphoma have been reported. Further studies are needed to clarify the role of EBV in the HT of FL.

    DOI: 10.3960/jslrt.23060

    Web of Science

    Scopus

    PubMed

    CiNii Research

  10. <i>MYD88</i> mutation-positive indolent B-cell lymphoma with CNS involvement: Bing-Neel syndrome mimickers

    Takeda, K; Okazaki, S; Minami, R; Ichiki, A; Yamaga, Y; Nakajima, K; Kitamura, K; Karube, K; Nishiyama, T

    Journal of Clinical and Experimental Hematopathology   64 巻 ( 3 ) 頁: 252 - 260   2024年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本リンパ腫学会  

    MYD88 p.L265P mutation occurs in over 90% of Waldenström’s macroglobulinemia (WM), which is characterized by lymphoplasmacytic lymphoma (LPL) with monoclonal IgM. WM requires careful diagnosis due to overlapping features with other B-cell malignancies. Bing–Neel syndrome (BNS), a rare complication of WM, involves central nervous system (CNS) invasion. This report describes two cases of morphologically low-grade B-cell lymphoma in the bone marrow accompanied by the presence of a large B-cell lymphoma in the brain and a common MYD88 p.L265P mutation, which were eventually established as BNS mimickers. Although the two components in these cases showed the same identical light-chain restriction, different immunoglobulin heavy-chain rearrangement peaks indicated distinct lymphoma stem cells for CNS and bone marrow lesions. These clinical cases emphasize the challenges in diagnosing BNS. Based on the findings, biopsy is recommended for accurate identification of the clonal relationship and MYD88 mutation status.

    DOI: 10.3960/jslrt.24033

    Web of Science

    Scopus

    PubMed

    CiNii Research

  11. Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An LLMPP Study

    Feldman, AL; Dasari, S; Rimsza, LM; Scott, DW; Oishi, N; Amador, C; Campo, E; Chan, WC; Cook, JR; Delabie, J; Farinha, P; Fu, K; Greiner, TC; Inghirami, G; Iqbal, J; Jaffe, ES; Ondrejka, SL; Ott, G; Pittaluga, S; Raess, P; Rosenwald, A; Savage, KJ; Slack, G; Slager, SL; Song, JY; Staudt, LM; Wright, G; Wang, HW; Zeng, Y; Yoshino, T; Wu, XJ; Wilcox, RA; Wang, XJ; Satou, A; Perry, AM; Miranda, R; Medeiros, LJ; Maurer, MJ; Mou, E; Ko, YH; Karube, K; Kahl, BS; Jiang, LY; Jaye, DL; de Leval, L; Chen, WN; Chapman-Fredricks, JR; Cerhan, JR; Barrionuevo, C; Ansell, SM; Aljudi, A

    BLOOD   142 巻   2023年11月

  12. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of pleural origin

    Urano, Y; Karube, K; Shiraki, Y

    PATHOLOGY INTERNATIONAL   73 巻 ( 11 ) 頁: 560 - 562   2023年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Pathology International  

    DOI: 10.1111/pin.13372

    Web of Science

    Scopus

    PubMed

  13. Masqueraded mastocytosis with prominent crystal-storing histiocytic infiltration

    Karube, K; Takeuchi, K

    BLOOD   142 巻 ( 16 ) 頁: 1404 - 1404   2023年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Blood  

    DOI: 10.1182/blood.2023021961

    Web of Science

    Scopus

    PubMed

  14. 症例 子宮体癌との鑑別を要した異型ポリープ状腺筋腫の1例

    川上 由香, 伊良波 裕子, 下地 裕子, 青木 陽一, 玉城 智子, 加留部 謙之輔, 西江 昭弘

    臨床放射線   68 巻 ( 10 ) 頁: 1001 - 1005   2023年10月

     詳細を見る

    出版者・発行元:金原出版  

    DOI: 10.18888/rp.0000002481

    CiNii Research

  15. The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (vol 36, pg 1720, 2022)

    Alaggio, R; Amador, C; Anagnostopoulos, I; Attygalle, AD; Araujo, IBD; Berti, E; Bhagat, G; Borges, AM; Boyer, D; Calaminici, M; Chadburn, A; Chan, JKC; Cheuk, W; Chng, WJ; Choi, JK; Chuang, SS; Coupland, SE; Czader, M; Dave, SS; de Jong, D; Di Napoli, A; Du, MQ; Elenitoba-Johnson, KS; Ferry, J; Geyer, J; Gratzinger, D; Guitart, J; Gujral, S; Harris, M; Harrison, CJ; Hartmann, S; Hochhaus, A; Jansen, PM; Karube, K; Kempf, W; Khoury, J; Kimura, H; Klapper, W; Kovach, AE; Kumar, S; Lazar, AJ; Lazzi, S; Leoncini, L; Leung, N; Leventaki, V; Li, XQ; Lim, MS; Liu, WP; Louissaint, A ; Marcogliese, A; Medeiros, LJ; Michal, M; Miranda, RN; Mitteldorf, C; Montes-Moreno, S; Morice, W; Nardi, V; Naresh, KN; Natkunam, Y; Ng, SB; Oschlies, I; Ott, G; Parrens, M; Pulitzer, M; Rajkumar, SV; Rawstron, AC; Rech, K; Rosenwald, A; Said, J; Sarkozy, C; Sayed, S; Saygin, C; Schuh, A; Sewell, W; Siebert, R; Sohani, AR; Suzuki, R; Tooze, R; Traverse-Glehen, A; Vega, F; Vergier, B; Wechalekar, AD; Wood, B; Xerri, L; Xiao, WB; Akinola, NO; Akkari, Y; Allende, LM; Aozasa, K; Araujo, I; Arcaini, L; Ardeshna, KM; Asano, N; Attarbaschi, A; Bacon, CM; Barrans, SL; Batchelor, T; Battistella, M; Baughn, LB; Behdad, A; Berentsen, S; Bianchi, G; Bledsoe, J; Borchmann, P; Bower, M; Buldini, B; Burger, JA; Burkhardt, B; Cassaday, RD; Cazzaniga, G; Cerf-Bensussan, N; Cesarman, E; Chandy, M; Chapman, JR; Chapuy, B; Chen, XY; Cheng, CL; Chiattone, C; Chiorazzi, N; Cook, LB; Cooper, WA; Corboy, GP; Cowan, AJ; Cozzolino, I; Cree, IA; d'Amore, ESG; Davies, AJ; Deckert, M; Delabie, J; Demicco, EG; Deshpande, V; Diepstra, A; Dierickx, D; Dunleavy, K; Eichhorst, B; Ennishi, D; Fajgenbaum, DC; Farinha, P; de Larrea, CF; Fisher, KE; Fitzgibbon, J; Flanagan, M; Fromm, J; Garcia, JF; Geddie, WR; Gertz, M; Gopal, A; Gopal, S; Greipp, PT; Gru, A; Gupta, R; Hansmann, ML; Hebeda, KM; Herfarth, K; Herling, M; Hermine, O; Khe, HX; Hodge, J; Hu, SM; Huang, YH; Hung, YP; Hunger, S; Inaba, H; Inagaki, H; Iqbal, J; Ishitsuka, K; Iwaki, N; Iwatsuki, K; Jain, N; Jeon, YK; Kadin, M; Kaji, S; Kakkar, A; Karadimitris, A; Kataoka, K; Kato, S; Kersten, MJ; Ketterling, RP; Kim, JE; Kratz, CP; Kridel, R; Kristinsson, S; Küppers, R; Kuzu, I; Kwong, YL; Lacasce, A; Lamant-Rochaix, L; Lamy, T; Landgren, O; Laskar, S; Laskin, WB; Lenz, G; Li, SY; Di Li, G; Lin, P; Locatelli, F; Lorsbach, RB; Lossos, I; Loughran, TP Jr; Macon, WR; Maleszewski, JJ; Malhotra, P; Marafioti, T; Maruyama, D; Marx, A; Mbulaiteye, SM; Meignin, V; Mejstrikova, E; Michelow, P; Miettinen, M; Miles, RR; Miyoshi, H; Molina, TJ; Mollejo, M; Momose, S; Mori, T; Morice, WG; Nadel, B; Nagai, H; Nagane, M; Nair, R; Nakamura, N; Nakazawa, A; Nasr, S; Nicholson, AG; Nicolae, A; Ohgami, RS; Oishi, N; Olson, TS; Ortonne, N; Paiva, B; Pan-Hammarström, Q; Parihar, M; Paulli, M; Petersen, A; Picarsic, J; Pileri, A; Pimpinelli, N; Plaza, JA; Rabin, KR; Raderer, M; Rai, K; Randen, U; Rao, H; Robson, A; Rochford, R; Rosenquist, R; Rossi, D; Rossi, ED; Rule, S; Rymkiewicz, G; Sabattini, E; Saha, V; Sakata-Yanagimoto, M; Sander, CA; Sangueza, JM; Sangüeza, OP; Santucci, M; Sato, Y; Satou, A; Schafernak, KT; Schmitt, F; Semenzato, G; Sengar, M; Shanafelt, T; Shimada, K; Slack, GW; Slager, S; Soffietti, R; Solomon, DA; Stamatopoulos, K; Steidl, C; Stilgenbauer, S; Sukswai, N; Takeuchi, K; Tallini, G; Tamaru, J; Tan, SY; Tembhare, P; Tiacci, E; Tokura, Y; Tournilhac, O; Treon, S; Truemper, L; Tsukasaki, K; van Rhee, F; Varghese, A; Vermeer, MH; Vielh, P; Walker, B; Wang, M; Wang, HY; Wang, Z; Watanabe, T; Weigert, O; Wein-Stock, D; Whittaker, SJ; Willemze, R; Woessmann, W; Wu, CJ; Yamaguchi, M; Yamamoto, H; Yamashita, D; Yang, SM; Yang, DT; Yasuda, T; Yin, WH; Zen, Y; Zhao, S; Zhao, WL

    LEUKEMIA   37 巻 ( 9 ) 頁: 1944 - 1951   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Leukemia  

    Correction to: Leukemia, published online 22 June 2022 At the time of original publication, there was an incomplete listing of contributing authors and their institutions. This revision corrects those omissions.

    DOI: 10.1038/s41375-023-01962-5

    Web of Science

    Scopus

    PubMed

  16. Prognostic impact of highly solid component in early-stage solid lung adenocarcinoma

    Kato, T; Iwano, S; Hanamatsu, Y; Nakaguro, M; Emoto, R; Okado, S; Sato, K; Noritake, O; Nakanishi, K; Kadomatsu, Y; Ueno, H; Ozeki, N; Nakamura, S; Fukumoto, K; Takeuchi, T; Karube, K; Matsui, S; Chen-Yoshikawa, TF

    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY   13 巻 ( 9 ) 頁: 5641 - +   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Quantitative Imaging in Medicine and Surgery  

    Background: Based on computed tomography (CT) findings of lung cancer, solid nodules have a much worse prognosis than subsolid nodules, even if the nodules are subcentimeter in size. There is, however, no systematic method for determining the prognosis of solid tumors on CT. This study aimed to discover the prognostic factor of early-stage solid lung adenocarcinoma using three-dimensional CT volumetry. Methods: Patients with pathological stage I solid lung adenocarcinoma who underwent complete resection between 2007 and 2012 were selected in this retrospective study. Clinicopathological data and preoperative multidetector CT findings, such as tumor size on the two-dimensional axial image, three-dimensional tumor volume between -600 and 199 HU, and three-dimensional solid volume between 0 and 199 HU, which corresponded to highly solid components, were compared between recurrence and non-recurrence. Furthermore, these radiological values were compared to pathological invasive volume (PIV). Results: During this time, 709 patients had their lung cancer completely removed. From this cohort, 90 patients with pathological stage I solid lung adenocarcinoma were selected. In addition, recurrence was found in 26 patients (28.9%). Although two-dimensional axial image, serum carcinoembryonic antigen (CEA) level, and SUVmax on 18F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/ CT) did not differ statistically between recurrent and non-recurrent patients, three-dimensional tumor and solid tumor volume did. Multivariate analysis indicated that three-dimensional solid tumor volume [hazard ratio: 2.440; 95% confidence interval (CI): 1.110-5.361, P=0.026] and epidermal growth factor receptor (EGFR) mutation (hazard ratio: 4.307; 95% CI: 1.328-13.977, P=0.015) were significantly associated with disease-free survival (DFS). When three-dimensional tumor and solid tumor volume were compared to PIV, three-dimensional solid tumor volume (3,091 mm3 on average) showed a highly similar value with PIV (2,930 mm3 on average), whereas three-dimensional tumor volume (6,175 mm3 on average) was significantly larger than PIV (P<0.001). Conclusions: In patients with early-stage solid lung adenocarcinoma, the measurement of threedimensional solid tumor volume, which is correlated with PIV, accurately predicted the postoperative outcome.

    DOI: 10.21037/qims-23-36

    Web of Science

    Scopus

    PubMed

  17. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells

    Satou, A; Takahara, T; Yamashita, D; Seki, M; Kato, S; Tanioka, F; Tsuyuki, T; Wada, E; Sakurai, K; Karube, K; Tsuzuki, T; Nakamura, S

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   47 巻 ( 8 ) 頁: 897 - 906   2023年8月

     詳細を見る

    記述言語:英語   出版者・発行元:American Journal of Surgical Pathology  

    Peripheral T-cell lymphomas (PTCLs), particularly nodal lymphomas of T-follicular helper cell origin, may include Hodgkin/Reed-Sternberg (HRS)-like cells in their microenvironment. These HRS-like cells are morphologically indistinguishable from HRS cells of classic Hodgkin lymphoma (CHL). Therefore, PTCLs with HRS-like cells pose a differential diagnosis vis-à-vis CHL. A previous study reported that, in contrast to HRS cells, programmed death-ligand 1 (PD-L1) expression is rare in HRS-like cells of PTCLs and suggested that PD-L1 immunohistochemistry is useful to differentiate HRS cells and HRS-like cells. In this study, we analyzed 21 patients with PTCL with HRS-like cells and 34 patients with CHL and assessed the diagnostic utility of STAT6, pSTAT6, and pSTAT3 immunohistochemistry in distinguishing HRS cells from HRS-like cells. In addition, we also performed PD-L1 immunohistochemistry to reconfirm its utility in distinguishing the 2 diseases. Compared with HRS cells in CHLs, HRS-like cells in PTCLs showed significantly less positivity for STAT6 (9.6% vs. 70%, P<0.001), pSTAT6 (9.6% vs. 70%, P<0.001), and PD-L1 (9.6% vs. 85%, P<0.001). Thus, we reconfirmed the diagnostic utility of PD-L1 immunohistochemistry in distinguishing CHLs from PTCLs with HRS-like cells. In contrast, both HRS-like and HRS cells were highly associated with pSTAT3 expression, with no significant difference in positive cell frequency (86% vs. 91%, P=0.66). On the basis of these findings, we conclude that, in addition to PD-L1, STAT6 and pSTAT6 immunohistochemistry are helpful diagnostic tools to distinguish CHLs from PTCLs with HRS-like cells.

    DOI: 10.1097/PAS.0000000000002062

    Web of Science

    Scopus

    PubMed

  18. A Comprehensive Study of the Immunophenotype and its Clinicopathologic Significance in Adult T-Cell Leukemia/Lymphoma

    Tamaki, T; Karube, K; Sakihama, S; Tsuruta, Y; Awazawa, R; Hayashi, M; Nakada, N; Matsumoto, H; Yagi, N; Ohshiro, K; Nakazato, I; Kitamura, S; Nishi, Y; Miyagi, T; Yamaguchi, S; Nakachi, S; Morishimaj, S; Masuzakij, H; Takahashik, K; Fukushimac, T; Wadaa, N

    MODERN PATHOLOGY   36 巻 ( 8 ) 頁: 100169   2023年8月

     詳細を見る

    記述言語:英語   出版者・発行元:Modern Pathology  

    Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell tumor caused by human T-lymphotropic virus type 1 (HTLV-1). The typical ATLL immunophenotypes are described in the 2017 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (positive: CD2, CD3, CD5, CD4, and CD25; negative: CD7, CD8, and cytotoxic markers; and partially positive: CD30, CCR4, and FOXP3). However, limited studies are available on the expression of these markers, and their mutual relationship remains unknown. Furthermore, the expression status of novel markers associated with T-cell lymphomas, including Th1 markers (T-bet and CXCR3), Th2 markers (GATA3 and CCR4), T follicular helper markers (BCL6, PD1, and ICOS), and T-cell receptor (TCR) markers, and their clinicopathologic significance is unclear. In this study, we performed >20 immunohistochemical stains in 117 ATLL cases to determine the comprehensive immunophenotypic profile of ATLL, which were compared on the basis of clinicopathologic factors, including morphologic variants (pleomorphic vs anaplastic), biopsy locations, treatments, Shimoyama classification-based clinical subtype, and overall survival. CD3+/CD4+/CD25+/CCR4+ was considered a typical immunophenotype of ATLL, but approximately 20% of cases did not conform to this pattern. Simultaneously, the following new findings were obtained: (1) most cases were negative for TCR-β and TCR-δ (104 cases, 88.9%), indicating the usefulness of negative conversion of TCR expression to provide differentiation from other T-cell tumors; (2) the positivity of CD30 and CD15 and the negativity of FOXP3 and CD3 were significantly associated with anaplastic morphology; and (3) atypical cases, such as T follicular helper marker-positive (12 cases, 10.3%) and cytotoxic molecule-positive cases (3 cases, 2.6%), were identified. No single markers could predict the overall survival among patients with acute/lymphoma subtypes of ATLL. The results of this study illustrate the diversity of ATLL phenotypes. In T-cell tumors occurring in HTLV-1 carriers, the possibility of ATLL should not be eliminated even when the tumor exhibits an atypical phenotype, and the confirmation of HTLV-1 in the tissue is recommended.

    DOI: 10.1016/j.modpat.2023.100169

    Web of Science

    Scopus

    PubMed

  19. Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints

    Gonzalez-Farre, B; Ramis-Zaldivar, JE; de Anta, NC; Rivas-Delgado, A; Nadeu, F; Salmeron-Villalobos, J; Enjuanes, A; Karube, K; Balague, O; Cobo, F; Kelleher, N; Victoria, I; Veloza, L; Teixido, C; Gine, E; Lopez-Guerra, M; Quintanilla-Martinez, L; Lopez-Guillermo, A; Salaverria, I; Campo, E

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   47 巻 ( 2 ) 頁: 202 - 211   2023年2月

     詳細を見る

    記述言語:英語   出版者・発行元:American Journal of Surgical Pathology  

    Intravascular large B-cell lymphoma (IVLBCL) is an uncommon lymphoma with an aggressive clinical course characterized by selective growth of tumor cells within the vessels. Its pathogenesis is still uncertain and there is little information on the underlying genomic alterations. In this study, we performed a clinicopathologic and next-generation sequencing analysis of 15 cases of IVLBCL using a custom panel for the detection of alterations in 68 recurrently mutated genes in B-cell lymphomagenesis. Six patients had evidence of hemophagocytic syndrome. Four patients presented concomitantly a solid malignancy. Tumor cells outside the vessels were observed in 7 cases, 2 with an overt diffuse large B-cell cell lymphoma. In 4 samples, tumor cells infiltrated lymphatic vessel in addition to blood capillaries. Programmed death-ligand 1 (PD-L1) was positive in tumor cells in 4 of 11 evaluable samples and in macrophages intermingled with tumor cells in 8. PD-L1 copy number gains were identified in a higher proportion of cases expressing PD-L1 than in negative tumors. The most frequently mutated gene was PIM1 (9/15, 60%), followed by MYD88 L265P and CD79B (8/15, 53% each). In 6 cases, MYD88 L265P and CD79B mutations were detected concomitantly. We also identified recurrent mutations in IRF4, TMEM30A, BTG2, and ETV6 loci (4/15, 27% each) and novel driver mutations in NOTCH2, CCND3, and GNA13, and an IRF4 translocation in 1 case each. The mutational profile was similar in patients with and without evidence of hemophagocytic syndrome and in cases with or without dissemination of tumor cells outside the vessels. Our results confirm the relevance of mutations in B-cell receptor/nuclear factor-κB signaling and immune escape pathways in IVLBCL and identify novel driver alterations. The similar mutational profile in tumors with extravascular dissemination suggests that these cases may also be considered in the spectrum of IVLBCL.

    DOI: 10.1097/PAS.0000000000001978

    Web of Science

    Scopus

    PubMed

  20. The correlation between HTLV-1 and Whipple's disease in a Japanese population: A case series

    Furugen Tomonori, Kinjo Tetsu, Hokama Akira, Furukawa Kojiro, Karube Kennosuke

      42 巻 ( 1-4 ) 頁: 21 - 28   2023年

     詳細を見る

    記述言語:英語  

    Purpose: Whippleʼs disease (WD) is a rare systemic disease caused by Tropheryma whipplei. It is predominantly diagnosed in middle-aged Caucasian men, and its association with immunosuppression and human leukocyte antigen (HLA)-B27 has been discussed; however, these studies are limited to western countries. Herein, we analyzed five WD cases and eight previously described WD cases in the Japanese population.
    Results: None of the patients were under immunosuppressive treatment or HLA-B27-positive. In 10/13 cases checking anti-HTLV-1 antibody, 6/10 (60%) cases were carriers of human T-cell leukemia virus type 1 (HTLV-1). All patients were treated with antibiotics, and their symptoms diminished promptly. The prognosis for these cases was excellent, and one patient developed the smoldering type adult T-cell leukemia/lymphoma, but no progression to aggressive type adult T-cell leukemia/lymphoma was observed.
    Conclusion: These findings probably support the findings that the immunosuppressive effect of HTLV-1 triggers WD in Japanese patients. It is recommended to evaluate the presence of HTLV-1 antibody in the blood of WD patients in HTLV-1 endemic areas for the clarification of the accurate pathogenesis and appropriate clinical follow-up. Ryukyu Med. J., 42 (1~4) 21~28, 2023

    CiNii Research

  21. Genomic profiling for clinical decision making in lymphoid neoplasms

    de Leval, L; Alizadeh, AA; Bergsagel, PL; Campo, E; Davies, A; Dogan, A; Fitzgibbon, J; Horwitz, SM; Melnick, AM; Morice, WG; Morin, RD; Nadel, B; Pileri, SA; Rosenquist, R; Rossi, D; Salaverria, I; Steidl, C; Treon, SP; Zelenetz, AD; Advani, RH; Allen, CE; Ansell, SM; Chan, WC; Cook, JR; Cook, LB; D'Amore, F; Dirnhofer, S; Dreyling, M; Dunleavy, K; Feldman, AL; Fend, F; Gaulard, P; Ghia, P; Gribben, JG; Hermine, O; Hodson, DJ; Hsi, ED; Inghirami, G; Jaffe, ES; Karube, K; Kataoka, K; Klapper, W; Kim, WS; King, RL; Ko, YH; LaCasce, AS; Lenz, G; Martin-Subero, JI; Piris, MA; Pittaluga, S; Pasqualucci, L; Quintanilla-Martinez, L; Rodig, SJ; Rosenwald, A; Salles, GA; San-Miguel, J; Savage, KJ; Sehn, LH; Semenzato, G; Staudt, LM; Swerdlow, SH; Tam, CS; Trotman, J; Vose, JM; Weigert, O; Wilson, WH; Winter, JN; Wu, CJ; Zinzani, PL; Zucca, E; Bagg, A; Scott, DW

    BLOOD   140 巻 ( 21 ) 頁: 2193 - 2227   2022年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Blood  

    With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.

    DOI: 10.1182/blood.2022015854

    Web of Science

    Scopus

    PubMed

  22. INFANT WITH NEUROBLASTOMA STAGE 4S REQUIRING LIVING DONOR LIVER TRANSPLANTATION

    Yamamori, A; Muramatsu, H; Wakamatsu, M; Kataoka, S; Tsuyuki, Y; Nishio, N; Shimoyama, Y; Karube, K; Ogura, Y; Takahashi, Y

    PEDIATRIC BLOOD & CANCER   69 巻   2022年11月

     詳細を見る

  23. Acute type adult T-cell leukemia cells proliferate in the lymph nodes rather than in peripheral blood

    Mizuguchi, M; Takatori, M; Sakihama, S; Yoshita-Takahashi, M; Imaizumi, N; Takahashi, Y; Hasegawa, H; Karube, K; Fukushima, T; Nakamura, M; Tanaka, Y

    CANCER GENE THERAPY   29 巻 ( 11 ) 頁: 1570 - 1577   2022年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Gene Therapy  

    A massive increase in the number of mature CD4+ T-cells in peripheral blood (PB) is a defining characteristic of acute type of adult T-cell leukemia (ATL). To date, the site of proliferation of ATL cells in the body has been unclear. In an attempt to address this question, we examined the expression of the proliferation marker, Ki-67, in freshly isolated ATL cells from PB and lymph nodes (LNs) of patients with various types of ATL. Our findings reveal that LN-ATL cells display higher expression of the Ki-67 antigen than PB-ATL cells in acute type patients. The gene expression of T-cell quiescence regulators such as Krüppel-like factor 2/6 and forkhead box protein 1 was substantially high in acute type PB-ATL cells. The expression of human telomerase reverse transcriptase, which is involved in T-cell expansion, was significantly low in PB-ATL cells from acute type patients, similar to that in normal resting T-cells. These findings suggest that ATL cells proliferate in the LNs rather than in PB.

    DOI: 10.1038/s41417-022-00475-0

    Web of Science

    Scopus

    PubMed

  24. Wide excision alone for elderly patients aged &gt; 70 years old with soft tissue sarcomas

    Aoki, Y; Tome, Y; Oshiro, H; Katsuki, R; Tamaki, T; Wada, N; Karube, K; Nishida, K

    MEDICINE   101 巻 ( 36 ) 頁: e30127   2022年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Medicine (United States)  

    The purpose of the present study was to clarify clinical outcomes of elderly patients with soft tissue sarcoma who underwent surgery neither with neoadjuvant nor adjuvant chemotherapy. The median follow-up period was 46.3 (range 6.7-99.0) months. All patients underwent surgical resections. R0 margins were achieved in 24 cases (92.3%) and R1 margins in 2 cases (7.7%). The 1-, 2-, and 5-year sarcoma-specific survival (SSS) rates were 92.3%, 88.5%, and 83.8%, respectively. Multivariate analysis showed no significant risk factors for SSS. No significant relationship of histological grades and local recurrences (P =.56) or distant metastases (P =.54) was shown. In the current study, we observed a comparable survival ratio, despite no neoadjuvant or adjuvant chemotherapies performed. Tumor resections with adequate margins might, at least in part, have contributed to the decent survival ratio regardless of histological grade. Twenty-six consecutive patients aged ≥ 70 years, who underwent surgical resections of soft tissue sarcoma between January 2013 and December 2019, were included. SSS were analyzed by the Kaplan-Meier method, and the relationships between SSS and clinical parameters were evaluated by Cox proportional hazards analysis.

    DOI: 10.1097/MD.0000000000030127

    Web of Science

    Scopus

    PubMed

  25. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Alaggio, R; Amador, C; Anagnostopoulos, I; Attygalle, AD; Araujo, IBD; Berti, E; Bhagat, G; Borges, AM; Boyer, D; Calaminici, M; Chadburn, A; Chan, JKC; Cheuk, W; Chng, WJ; Choi, JK; Chuang, SS; Coupland, SE; Czader, M; Dave, SS; de Jong, D; Du, MQ; Elenitoba-Johnson, KS; Ferry, J; Geyer, J; Gratzinger, D; Guitart, J; Gujral, S; Harris, M; Harrison, CJ; Hartmann, S; Hochhaus, A; Jansen, PM; Karube, K; Kempf, W; Khoury, J; Kimura, H; Klapper, W; Kovach, AE; Kumar, S; Lazar, AJ; Lazzi, S; Leoncini, L; Leung, N; Leventaki, V; Li, XQ; Lim, MS; Liu, WP; Louissaint, A ; Marcogliese, A; Medeiros, LJ; Michal, M; Miranda, RN; Mitteldorf, C; Montes-Moreno, S; Morice, W; Nardi, V; Naresh, KN; Natkunam, Y; Ng, SB; Oschlies, I; Ott, G; Parrens, M; Pulitzer, M; Rajkumar, SV; Rawstron, AC; Rech, K; Rosenwald, A; Said, J; Sarkozy, C; Sayed, S; Saygin, C; Schuh, A; Sewell, W; Siebert, R; Sohani, AR; Tooze, R; Traverse-Glehen, A; Vega, F; Vergier, B; Wechalekar, AD; Wood, B; Xerri, L; Xiao, WB

    LEUKEMIA   36 巻 ( 7 ) 頁: 1720 - 1748   2022年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Leukemia  

    We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

    DOI: 10.1038/s41375-022-01620-2

    Web of Science

    Scopus

    PubMed

  26. Spindle cell tumor with histiocytic and myogenic marker expression in the lymph node of a human T-cell leukemia virus type 1 carrier

    Kubo, T; Hirayama, Y; Sakihama, S; Kikuchi, T; Hirohashi, Y; Tsujiwaki, M; Karube, K; Hasegawa, T; Torigoe, T

    PATHOLOGY RESEARCH AND PRACTICE   234 巻   頁: 153935   2022年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Pathology Research and Practice  

    Carriers of oncogenic human T-cell leukemia virus type 1 (HTLV-1) can develop adult T-cell leukemia/lymphoma (ATLL). While an increasing number of animal models of HTLV-1 infection have revealed that malignant tumors with a histiocytic phenotype can arise, they have not been reported in humans. Here, we present a 79-year-old female HTLV-1 carrier who presented with a swollen lymph node. Histological examination revealed that the lymph node was replaced with a malignant spindle cell tumor, but not ATLL. Immunohistochemical analysis indicated that the tumor was positive for histiocytic (CD68 and CD163) and myogenic (α-smooth muscle actin, desmin, and caldesmon) markers, suggesting some differential diagnoses. We could not reach a definitive diagnosis under the current notion of the disease entity. In addition, we could not provide an exact causal relationship between HTLV-1 infection and the development of the current tumor. Nevertheless, this tumor may be a human counterpart of murine HTLV-1-related histiocytic tumors. Curiously, the tumor showed a good response to chemotherapy with the combination of cyclophosphamide, vincristine, and prednisone, a standard approach for ATLL. This case might represent a novel entity of an HTLV-1-related malignant tumor. Further accumulation of case reports will certainly contribute to our understanding of human HTLV-1-related disease and the mechanism of viral oncogenesis.

    DOI: 10.1016/j.prp.2022.153935

    Web of Science

    Scopus

    PubMed

  27. Genetic Alterations in Adult T-Cell Leukemia/Lymphoma: Novel Discoveries with Clinical and Biological Significance

    Sakihama, S; Karube, K

    CANCERS   14 巻 ( 10 )   2022年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancers  

    Adult T-cell leukemia/lymphoma (ATLL) is a refractory T-cell neoplasm that develops in human T-cell leukemia virus type-I (HTLV-1) carriers. Large-scale comprehensive genomic analyses have uncovered the landscape of genomic alterations of ATLL and have identified several altered genes related to prognosis. The genetic alterations in ATLL are extremely enriched in the T-cell receptor/nuclear factor-κB pathway, suggesting a pivotal role of deregulation in this pathway in the transformation of HTLV-1-infected cells. Recent studies have revealed the process of transformation of HTLV-1-infected cells by analyzing longitudinal samples from HTLV-1 carriers and patients with overt ATLL, an endeavor that might enable earlier ATLL diagnosis. The latest whole-genome sequencing study discovered 11 novel alterations, including CIC long isoform, which had been over-looked in previous studies employing exome sequencing. Our study group performed the targeted sequencing of ATLL in Okinawa, the southernmost island in Japan and an endemic area of HTLV-1, where the comprehensive genetic alterations had never been analyzed. We found associations of genetic alterations with HTLV-1 strains phylogenetically classified based on the tax gene, an etiolog-ical virus factor in ATLL. This review summarizes the genetic alterations in ATLL, with a focus on their clinical significance, geographical heterogeneity, and association with HTLV-1 strains.

    DOI: 10.3390/cancers14102394

    Web of Science

    Scopus

    PubMed

  28. Elevation of the Plasma Levels of TNF Receptor 2 in Association with Those of CD25, OX40, and IL-10 and HTLV-1 Proviral Load in Acute Adult T-Cell Leukemia

    Kato, M; Imaizumi, N; Tanaka, R; Mizuguchi, M; Hayashi, M; Miyagi, T; Uchihara, J; Ohshiro, K; Todoroki, J; Karube, K; Masuzaki, H; Tanaka, Y; Fukushima, T

    VIRUSES-BASEL   14 巻 ( 4 )   2022年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Viruses  

    Adult T-cell leukemia/lymphoma (ATL) cells express TNF receptor type-2 (TNFR2) on their surface and shed its soluble form (sTNFR2). We previously reported that sTNFR2 levels were highly elevated in the plasma of patients with acute ATL. To investigate whether its quantitation would be helpful for the diagnosis or prediction of the onset of acute ATL, we examined the plasma levels of sTNFR2 in a large number of specimens obtained from a cohort of ATL patients and asymptomatic human T-cell leukemia virus type 1 (HTLV-1) carriers (ACs) and compared them to those of other candidate ATL biomarkers (sCD25, sOX40, and IL-10) by enzyme-linked immunosorbent assays (ELISA) and HTLV-1 proviral loads. We observed that sTNFR2 levels were significantly elevated in acute ATL patients compared to ACs and patients with other types of ATL (chronic, smoldering, and lymphoma). Importantly, sTNFR2 levels were significantly correlated with those of sCD25, sOX40, and IL-10, as well as proviral loads. Thus, the present study confirmed that an increase in plasma sTNFR2 levels is a biomarker for the diagnosis of acute ATL. Examination of plasma sTNFR2 alone or in combination with other ATL biomarkers may be helpful for the diagnosis of acute ATL.

    DOI: 10.3390/v14040751

    Web of Science

    Scopus

    PubMed

  29. Blastic plasmacytoid dendritic cell neoplasm with prominent intracytoplasmic vacuoles: A challenging diagnosis

    Karube, K; Nakada, N; Sakamoto, K; Takeuchi, K

    PATHOLOGY INTERNATIONAL   72 巻 ( 3 ) 頁: 211 - 213   2022年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Pathology International  

    DOI: 10.1111/pin.13201

    Web of Science

    Scopus

    PubMed

  30. ステロイドが著効した濾胞性T細胞リンパ腫

    立津 央, 今金 大輔, 野坂 生郷, 加留部 謙之輔, 本田 由美, 樋口 悠介, 安永 純一朗, 三上 芳喜, 松岡 雅雄

    臨床血液   63 巻 ( 11 ) 頁: 1497 - 1502   2022年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本血液学会  

    <p>濾胞性T細胞リンパ腫(follicular T-cell lymphoma, FTCL)は,WHO分類改訂4版で新たに定義された血管免疫芽球性T細胞リンパ腫と同じ濾胞性T細胞由来の末梢性T細胞リンパ腫である。今回,ステロイド投与のみで長期生存が得られたFTCLの1例を経験した。症例は,91歳の女性。3ヶ月続く全身リンパ節腫脹で受診し,壊死性リンパ節炎の診断後,再生検でFTCLの診断となった。全身のリンパ節腫脹,脾腫,胸水貯留を認め,本人・家族の希望で,化学療法を希望されず,ステロイドでの加療を行った。Prednisolone 100 mg/日の投与から開始し,6ヶ月後には,FDG-PET/CTで寛解を確認した。以後,少量ステロイド投与で3年以上,寛解を維持可能であった。本症例のようなステロイドの加療が奏効する濾胞ヘルパーT細胞を起源とするT細胞リンパ腫が存在することが示唆された。</p>

    DOI: 10.11406/rinketsu.63.1497

    PubMed

    CiNii Research

  31. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma

    Morichika, K; Karube, K; Sakihama, S; Watanabe, R; Kawaki, M; Nishi, Y; Nakachi, S; Okamoto, S; Takahara, T; Satou, A; Shimada, S; Shimada, K; Tsuzuki, T; Fukushima, T; Morishima, S; Masuzaki, H

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   45 巻 ( 6 ) 頁: 832 - 840   2021年6月

     詳細を見る

    記述言語:英語   出版者・発行元:American Journal of Surgical Pathology  

    On the basis of immunohistochemistry, diffuse large B-cell lymphoma (DLBCL) is categorized as a germinal center B-cell (GCB) or non-GCB subtype. Recent integrated genomic analyses have highlighted the importance of the JAK-STAT3 pathway in the molecular pathogenesis of DLBCL. However, its relevance to clinical outcomes remains controversial. Therefore, we evaluated the extent of the nuclear expression of phosphorylated STAT3 (pSTAT3), a surrogate marker of signal transducer and activator of transcription 3 (STAT3) activation, by immunohistochemistry. We also analyzed the potential relationship between pSTAT3 positivity (defined as ≥ 40% positive neoplastic cells) and clinicopathologic characteristics in 294 patients with DLBCL. pSTAT3 was detected in 122 patients (42%), with a higher rate in the non-GCB subtype than in the GCB subtype (57% vs. 28%, P < 0.001). Factors potentially activating STAT3, MYD88L265P, and Epstein-Barr virus-encoded small RNA were identified in the pSTAT3-positive non-GCB subtype, whereas the pSTAT3-positive GCB subtype often showed STAT3 mutations and lacked EZH2 mutations and the rearrangements of BCL2 and MYC. Multivariate analyses revealed that the pSTAT3-positive GCB subtype showed a favorable prognosis (HR: 0.17; 95% confidence interval, 0.04-0.7; P = 0.014). These findings suggest that pSTAT3 positivity may have a unique impact on the clinicopathologic characteristics of DLBCL, making it a promising novel marker for the favorable prognosis of patients with the GCB subtype.

    DOI: 10.1097/PAS.0000000000001691

    Web of Science

    Scopus

    PubMed

▼全件表示

科研費 2

  1. 新規病態:HTLV-1陽性HRS細胞を伴う成人T細胞白血病/リンパ腫の統合的解析

    研究課題/研究課題番号:23K27384  2023年4月 - 2027年3月

    科学研究費助成事業  基盤研究(B)

    加留部 謙之輔, 石塚 賢治, 加藤 光次, 福島 卓也, 佐藤 賢文, 下田 和哉

      詳細を見る

    担当区分:研究代表者 

    配分額:18460000円 ( 直接経費:14200000円 、 間接経費:4260000円 )

    申請者らが同定したHTLV-1関連の新規病態である Adult T-cell leukemia/lymphoma with HTLV-1 infected HRS-like cells (ATLL-HH)に関し
    て、腫瘍細胞及び腫瘍微小環境の両面から詳細な解析を行い、ATLL、CHLとの差異を明らかにする。具体的には臨床病理学的特徴の把握、網羅
    的遺伝子解析、シングルセル解析を組み合わせて解析し、ひいてはATLL-HHの診断、治療の向上につなげることを目的とする。

  2. HTLV-1ウイルス遺伝子産物の組織内同定法の開発とその病理学的意義の解明

    研究課題/研究課題番号:19K07438  2019年4月 - 2022年3月

    科学研究費助成事業  基盤研究(C)

    加留部 謙之輔

      詳細を見る

    担当区分:研究代表者 

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    ATLLの病変組織におけるHTLV-1ウイルスの同定法として、HBZ-in situ hybridization法を新しく開発する。この結果をHTLV-1ゲノム定量法、サザンブロット法などの従来より用いられている方法と比較しながら、その有効性および限界を把握し、日常診断において有用な検査にする。さらに、臨床経過や他のウイルス関連転写因子の発現との相関を解析しながら、ATLLの病態の解明に取り組む。
    成人T細胞白血病/リンパ腫(ATLL)の組織内、細胞内におけるヒトT細胞白血病ウイルス(Human T-cell leukemia virus, HTLV-1)の関与及び局在の同定を目的とした。
    結果として、HTLV-1ウイルスが産生するHBZのmRNAに対するin situ hybridization(HBZ in situ法)により、ATL腫瘍標本におけるウイルス粒子の同定が可能になった。さらに、HBZ in situ法の感度、特異度を明らかにするために定量PCRによるHTLV-1ウイルスゲノムの定量、及びサザンブロットによるウイルスの宿主ゲノムへの組み込みの実験系を確立した。
    ATLLの診断のためにはHTLV-1ウイルスの存在を証明する必要があるが、これまで手技が煩雑で生検体が必要なサザンブロット法が主流であった。今回の研究によりホルマリン固定標本でもウイルスの検出が可能になったことで、ATLLの病理学的診断における迅速性、正確性が大きく高まったと言える。さらに、病変組織中で直接ウイルスを「見る」ことができることで、ATLLの病態解明にも大きく貢献したと言える。